ENCAB923LQZ

Antibody against Homo sapiens ACO1

Homo sapiens
K562
characterized to standards
Homo sapiens
any cell type or tissue
partially characterized
Status
released
Source (vendor)
MBLI
Product ID
RN036PW
Lot ID
001
Characterized targets
ACO1 (Homo sapiens)
Host
rabbit
Clonality
polyclonal
Purification
affinity
Antigen description
Peptide, N-terminus of human ACO1
External resources

Characterizations

ACO1 (Homo sapiens)
Method: knockdown or knockout
Attachment from submitter
compliant
Caption
Western blot following shRNA against ACO1 in HepG2 whole cell lysate using ACO1 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against ACO1.ACO1 protein appears as the green band, Tubulin serves as a control and appears in red.
Submitted by
Xintao Wei
Lab
Brenton Graveley, UConn
ACO1 (Homo sapiens)
Method: knockdown or knockout
Attachment from submitter
compliant
Caption
Western blot following CRISPR against ACO1 in K562 whole cell lysate using ACO1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different CRISPR against ACO1.ACO1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.
Submitted by
Xintao Wei
Lab
Brenton Graveley, UConn
ACO1 (Homo sapiens)
K562
Method: immunoprecipitation
Attachment from submitter
compliant
Caption
IP-Western Blot analysis of K562 whole cell lysate using ACO1 specific antibody. Lane 1 is 1% of twenty million whole cell lysate input and lane 2 is 25% of IP enrichment using rabbit normal IgG (lanes under 'IgG'). Lane 3 is 1% of twenty million whole cell lysate input and lane 4 is 10% IP enrichment using rabbit polyclonal anti-ACO1antibody (lanes under 'ACO1').
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD
ACO1 (Homo sapiens)
Method: immunoprecipitation
Attachment from submitter
Caption
IP-WB analysis of K562 whole cell lysate using ACO1 specific antibody. Lane 1 is 2.5% of 0.5mg input lysate, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-ACO1(IRP1)(Human)pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD